Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors-Reference-Cited by-同舟云学术

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors

Published:2013-09 Issue:9 Volume:102 Page:3100-3109
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Ouellet Daniele,Grossmann Kenneth F.,Limentani Giselle,Nebot Noelia,Lan Kevin,Knowles Lara,Gordon Michael S.,Sharma Sunil,Infante Jeffrey R.,Lorusso Patricia M.,Pande Girish,Krachey Elizabeth C.,Blackman Samuel C.,Carson Stanley W.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference20 articles.

1. A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation;Laquerre;Mol Cancer Ther,2009

2. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial;Falchook;Lancet,2012

3. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

4. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial;Long;Lancet Oncol,2012

5. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals;Martinez;J Clin Pharmacol,2002

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

2. Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis;Clinical and Translational Science;2023-12

3. Food effects on gastrointestinal physiology and drug absorption;Drug Metabolism and Pharmacokinetics;2023-02

4. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five;Drug Discovery Today;2023-02

5. Evaluation of a Low‐Fat Low‐Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open‐Label, 2‐Part Study in Healthy Participants;Clinical Pharmacology in Drug Development;2023-01-20